Press release
Pheochromocytoma Pipeline 2025: Key Clinical Developments by Leading Global Innovators - DelveInsight | Highlighting Enterome, Perspective Therapeutics
Pheochromocytoma Pipeline 2025
With Pheochromocytoma increasingly prevalent worldwide and contributing to comorbidities such as diabetes, cardiovascular disorders, and certain cancers, the need for safer and more effective therapies is rising. DelveInsight reports that over three pharmaceutical and biotech companies are actively advancing more than three therapeutic candidates for Pheochromocytoma. These candidates are in various stages of clinical and preclinical development, reflecting significant innovation and dedication to tackling this pressing health concern.
DelveInsight's "Pheochromocytoma Pipeline Insight 2025" delivers a comprehensive analysis of the current R&D landscape. The report examines clinical trial progress, novel treatment approaches, mechanisms of action, competitive positioning, and strategic initiatives by key companies. It is an essential resource for researchers, healthcare investors, and decision-makers seeking insights into the evolving Pheochromocytoma therapeutics market and the breakthroughs driving its future direction.
Explore the Cutting-Edge Landscape of Pheochromocytoma Drug Development [https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Key Takeaways from the Pheochromocytoma Pipeline Report
*
DelveInsight's Pheochromocytoma pipeline report highlights a dynamic landscape, featuring over three active companies advancing more than three therapeutic candidates for Pheochromocytoma treatment.
*
In May 2025, the FDA approved belzutifan (Welireg), an oral HIF2 inhibitor, for both adult and pediatric patients ( greater than or equal to 12 years) with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). This approval represents the first oral systemic therapy for PPGLs, supported by the LITESPARK015 Phase II trial, which showed an overall response rate of approximately 26% and a median duration of response of about 20 months.
*
Earlier, in January 2025, the FDA accepted Merck's supplemental NDA for belzutifan in PPGL under Priority Review, setting a PDUFA target date of May 26, 2025.
*
Leading companies, including Enterome and Perspective Therapeutics, are actively exploring novel therapies aimed at improving the Pheochromocytoma treatment landscape. Notable pipeline candidates in various stages of development include EO2401 and others.
Pheochromocytoma Overview:
Pheochromocytoma is a rare tumor that generally develops in the adrenal medulla, the inner part of the adrenal glands. While typically benign, these tumors produce excessive catecholamines-mainly adrenaline (epinephrine) and noradrenaline (norepinephrine)-hormones critical to the body's stress response. Overproduction of these hormones can lead to serious, potentially life-threatening cardiovascular complications. Although most cases are diagnosed in individuals aged 30 to 50, pheochromocytomas can appear at any age.
Symptoms primarily result from elevated catecholamine levels and often include high blood pressure (either persistent or episodic), severe headaches, profuse sweating, palpitations, and rapid heart rate. Additional manifestations may include tremors, anxiety, and unexplained weight loss. Because these symptoms overlap with many other conditions, diagnosing pheochromocytoma can be difficult. In some instances, particularly when tumors are large, patients may also experience abdominal discomfort or a feeling of fullness.
Download the Pheochromocytoma sample report to know in detail about the Pheochromocytoma treatment market [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Pheochromocytoma Pipeline Analysis
The Pheochromocytoma pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Pheochromocytoma Market.
*
Categorizes Pheochromocytoma therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Pheochromocytoma drugs under development based on:
*
Stage of development
*
Pheochromocytoma Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Pheochromocytoma Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Pheochromocytoma Licensing agreements
*
Funding and investment activities supporting future Pheochromocytoma market advancement.
Unlock key insights into emerging Pheochromocytoma therapies and market strategies here: https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Pheochromocytoma Emerging Drugs
*
EO2401: Enterome
EO2401 is a pioneering, off-the-shelf peptide-based immunotherapy that employs OncoMimics Trademark -microbial-derived peptides that mimic tumor antigens IL13Ra2, BIRC5, and FOXM1-alongside a CD4+ helper peptide (UCP2) to trigger a precise immune response against tumor cells. The therapy is designed to train the immune system to identify and attack glioblastoma-like cells. EO2401 is being investigated in the Phase I/II SPENCER trial in combination with nivolumab for patients with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. Early results were presented at ASCO 2022, and the therapy has progressed to Phase II studies for pheochromocytoma.
Pheochromocytoma Pipeline Therapeutic Assessment
Pheochromocytoma Assessment by Product Type
- Mono
- Combination
- Mono/Combination
Pheochromocytoma By Stage
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Pheochromocytoma Assessment by Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Pheochromocytoma Assessment by Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Download sample pages to get an in-depth assessment of the emerging Pheochromocytoma therapies and key Pheochromocytoma companies [https://www.delveinsight.com/sample-request/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Contents
1. Report Introduction
2. Executive Summary
3. Pheochromocytoma Current Treatment Patterns
4. Pheochromocytoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pheochromocytoma Late-Stage Products (Phase-III)
7. Pheochromocytoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pheochromocytoma Discontinued Products
13. Pheochromocytoma Product Profiles
14. Pheochromocytoma Key Companies
15. Pheochromocytoma Key Products
16. Dormant and Discontinued Products
17. Pheochromocytoma Unmet Needs
18. Pheochromocytoma Future Perspectives
19. Pheochromocytoma Analyst Review
20. Appendix
21. Report Methodology
Request the sample PDF to get detailed insights about the Pheochromocytoma pipeline reports offerings [https://www.delveinsight.com/report-store/pheochromocytoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pheochromocytoma-pipeline-2025-key-clinical-developments-by-leading-global-innovators-delveinsight-highlighting-enterome-perspective-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pheochromocytoma Pipeline 2025: Key Clinical Developments by Leading Global Innovators - DelveInsight | Highlighting Enterome, Perspective Therapeutics here
News-ID: 4227971 • Views: …
More Releases from ABNewswire
Giant Cell Arteritis Pipeline 2025: Key Clinical Developments by 80+ Global Inno …
DelveInsight's, "Giant-Cell Arteritis - Pipeline Insight, 2025," report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Giant-Cell Arteritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Giant Cell Arteritis (GCA) becomes increasingly prevalent worldwide and…
Presbyopia Pipeline 2025: Innovative Clinical Developments by Leading Global Com …
DelveInsight's, "Presbyopia - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As presbyopia becomes increasingly prevalent worldwide and is associated with comorbidities such…
Primary Ciliary Dyskinesia Pipeline 2025: Groundbreaking Clinical Advancements b …
DelveInsight's, "Primary Ciliary Dyskinesia - Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
As Primary Ciliary Dyskinesia (PCD) increasingly impacts populations…
Periodontal Disease market is projected to experience significant growth by 2032 …
Periodontal Disease market is projected to experience significant growth by 2032, driven by major players such as Dentsply Sirona Inc., Envista Holdings Corporation, A-dec Inc., J. Morita Corp., Straumann Group, BIOLASE, BEGO GmbH & Co. KG, Ultradent Products, and Yoshida Dental.
Key factors contributing to this growth include the rising prevalence of Periodontal Disease, increased investments in R&D, and the introduction of novel and emerging therapies during the forecast period 2019-2032.
Additionally,…
More Releases for Pheochromocytoma
Pheochromocytoma Market Emerging Trends and Growth Prospects 2034
Introduction
Pheochromocytoma is a rare tumor arising from adrenal gland chromaffin cells, often associated with excessive catecholamine secretion that leads to hypertension and cardiovascular complications. Although considered an orphan disease due to its rarity, pheochromocytoma has gained increasing medical and research attention over the past decade. Advancements in genetic testing, diagnostic imaging, and molecular therapies have opened new opportunities for more accurate detection and effective management.
The global Pheochromocytoma Market is entering…
Rising Tumor Incidence Rates Fueling Growth In The Pheochromocytoma Market Drivi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Pheochromocytoma Market Size By 2025?
The market size of pheochromocytoma has been on a steady upward trend over the past years. It is projected to increase from $3.03 billion in 2024 to $3.17 billion in 2025, exhibiting a Compound Annual Growth Rate (CAGR) of 4.7%.…
Emerging Trends Influencing The Growth Of The Pheochromocytoma Market: Innovativ …
The Pheochromocytoma Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Pheochromocytoma Market Size Expected to Be by 2034?
The market size of pheochromocytoma has consistently expanded over the past few years. It's estimated to increase from $3.03 billion in 2024 to $3.17…
Top Factor Driving Pheochromocytoma Market Growth in 2025: Rising Tumor Incidenc …
How Big Is the Pheochromocytoma Market Expected to Be, and What Will Its Growth Rate Be?
The pheochromocytoma market has grown steadily in recent years. It will rise from $3.03 billion in 2024 to $3.17 billion in 2025, at a CAGR of 4.7%. This growth is attributed to increased healthcare spending, a rise in diagnoses and awareness, genetic research, and government initiatives.
The pheochromocytoma market is projected to see steady growth, reaching…
Pheochromocytoma Market Growth, Analysis And Forecast 2033
The new report published by The Business Research Company, titled Pheochromocytoma Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the pheochromocytoma market size has grown steadily in recent years. It will grow from $2.89 billion in 2023 to $3.03…
Pheochromocytoma Market Size, Share, Growth Forecast 2030
Pheochromocytoma, a rare but formidable adrenal gland tumor, has sparked increased interest in the medical community due to its complex nature. This article delves into the competitive landscape, future growth prospects, opportunities, drivers, restraints, and major market players in the Pheochromocytoma market. Additionally, we will explore current market trends and regional insights, shedding light on the evolving landscape of this niche market.
Download Free Pheochromocytoma Market Sample Report Here: (Including Full…
